<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241002224346&amp;utm_medium=rss&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241002224346&amp;utm_medium=rss&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 03 Oct 2024 02:43:46 +0000</lastbuilddate>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In patients with chronic Chagas cardiomyopathy at moderate to high risk of mortality, ICD did not reduce the risk of all-cause mortality. However, ICD significantly reduced the risk of SCD, pacing need, and heart failure hospitalization compared with amiodarone therapy. Further studies are warranted to confirm the evidence generated by this trial.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3169. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that ICD is more effective than amiodarone therapy for primary prevention of all-cause mortality in patients with chronic Chagas cardiomyopathy and moderate to high mortality risk, assessed by the Rassi score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: CHAGASICS is an open-label, randomized clinical trial. The study enrolled patients from 13 centers in Brazil from May 30, 2014, to August 13, 2021, with the last follow-up November 8, 2021. Patients with serological findings positive for Chagas disease, a Rassi risk score of at least 10 points (intermediate to high risk), and at least 1 episode of nonsustained ventricular tachycardia were eligible to participate. Data were analyzed from May 3, 2022, to June 16, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 1:1 to receive ICD or amiodarone (with a loading dose of 600 mg after randomization).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, and secondary outcomes included SCD, hospitalization for heart failure, and necessity of a pacemaker during the entire follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study was stopped prematurely for administrative reasons, with 323 patients randomized (166 in the amiodarone group and 157 in the ICD group), rather than the intended 1100 patients. Analysis was by intention to treat at a median follow-up of 3.6 (IQR, 1.8-4.4) years. Mean (SD) age was 57.4 (9.8) years, 185 patients (57.3%) were male, and the mean (SD) left ventricular ejection fraction was 37.0% (11.6%). There were 60 deaths (38.2%) in the ICD arm and 64 (38.6%) in the amiodarone group (hazard ratio [HR], 0.86 [95% CI, 0.60-1.22]; P = .40). The rates of SCD (6 [3.8%] vs 23 [13.9%]; HR, 0.25 [95% CI, 0.10-0.61]; P = .001), bradycardia requiring pacing (3 [1.9%] vs 27 [16.3%]; HR, 0.10 [95% CI, 0.03-0.34]; P &lt; .001), and heart failure hospitalization (14 [8.9%] vs 28 [16.9%]; HR, 0.46 [95% CI, 0.24-0.87]; P = .01) were lower in the ICD group compared with the amiodarone arm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with chronic Chagas cardiomyopathy at moderate to high risk of mortality, ICD did not reduce the risk of all-cause mortality. However, ICD significantly reduced the risk of SCD, pacing need, and heart failure hospitalization compared with amiodarone therapy. Further studies are warranted to confirm the evidence generated by this trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01722942.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356542</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3169>10.1001/jamacardio.2024.3169</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356542</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Martino Martinelli-Filho</dc:creator>
<dc:creator>José A Marin-Neto</dc:creator>
<dc:creator>Mauricio Ibrahim Scanavacca</dc:creator>
<dc:creator>Angelo Amato Vincenzo de Paola</dc:creator>
<dc:creator>Paulo de Tarso Jorge Medeiros</dc:creator>
<dc:creator>Ruth Owen</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Sergio Freitas de Siqueira</dc:creator>
<dc:creator>CHAGASICS investigators</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39356542</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3169</dc:identifier>
</item>
<item>
<title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356539</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3020>10.1001/jamacardio.2024.3020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356539</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:creator>Andrea Erriquez</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk-Reply</dc:title>
<dc:identifier>pmid:39356539</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3020</dc:identifier>
</item>
<item>
<title>Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.2612. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Greater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: SAVM vs sham control procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, -0.03 mm Hg; 95% CI, -2.5 to 2.5 mm Hg; P = .95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, -6.1% to 15.4%; P = .36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, -9.2% to 18.8%; P = .48).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04592445.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356530</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2612>10.1001/jamacardio.2024.2612</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356530</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Rajeev C Mohan</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Peter Fail</dc:creator>
<dc:creator>Parag Goyal</dc:creator>
<dc:creator>Scott L Hummel</dc:creator>
<dc:creator>Teona Zirakashvili</dc:creator>
<dc:creator>Tamaz Shaburishvili</dc:creator>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Christopher D Nielsen</dc:creator>
<dc:creator>Stanley J Chetcuti</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Rajiv Gulati</dc:creator>
<dc:creator>Luke Kim</dc:creator>
<dc:creator>Keith Benzuly</dc:creator>
<dc:creator>Sumeet S Mitter</dc:creator>
<dc:creator>Liviu Klein</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Ralph S Augostini</dc:creator>
<dc:creator>John E Blair</dc:creator>
<dc:creator>Krishna Rocha-Singh</dc:creator>
<dc:creator>Daniel Burkhoff</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Sami I Somo</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39356530</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2612</dc:identifier>
</item>
<item>
<title>Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Improvement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Guideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Estimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: All-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving β-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Improvement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356517</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3023>10.1001/jamacardio.2024.3023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356517</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Amber B Tang</dc:creator>
<dc:creator>Boback Ziaeian</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure</dc:title>
<dc:identifier>pmid:39356517</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3023</dc:identifier>
</item>
<item>
<title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356502/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 2. doi: 10.1001/jamacardio.2024.3017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356502/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356502</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3017>10.1001/jamacardio.2024.3017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356502</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahthavan Narendren</dc:creator>
<dc:creator>Anoop N Koshy</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk</dc:title>
<dc:identifier>pmid:39356502</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3017</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356087/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):3-5. doi: 10.1161/RES.0000000000000678. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356087/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356087</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000678>10.1161/RES.0000000000000678</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356087</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39356087</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000678</dc:identifier>
</item>
<item>
<title>Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39356086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):1. doi: 10.1161/RES.0000000000000679. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39356086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39356086</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000679>10.1161/RES.0000000000000679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39356086</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Editors and Editorial Board</dc:title>
<dc:identifier>pmid:39356086</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000679</dc:identifier>
</item>
<item>
<title>Maternal Blood Cell-Free RNA Signatures in Fetus With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39355931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 2. doi: 10.1161/CIRCRESAHA.124.325024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39355931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39355931</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325024>10.1161/CIRCRESAHA.124.325024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39355931</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew Alonzo</dc:creator>
<dc:creator>Zhaohui Xu</dc:creator>
<dc:creator>Yang Yu</dc:creator>
<dc:creator>Shiqiao Ye</dc:creator>
<dc:creator>Cankun Wang</dc:creator>
<dc:creator>Jerry Wang</dc:creator>
<dc:creator>Megan McNutt</dc:creator>
<dc:creator>Jakob Bering</dc:creator>
<dc:creator>Qin Ma</dc:creator>
<dc:creator>Karen Texter</dc:creator>
<dc:creator>Vidu Garg</dc:creator>
<dc:creator>Ming-Tao Zhao</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Maternal Blood Cell-Free RNA Signatures in Fetus With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:39355931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325024</dc:identifier>
</item>
<item>
<title>Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39355927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results identify RIα as a key negative regulator of cardiac contractile function, arrhythmia, and pathological remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.068858. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The heart expresses 2 main subtypes of cAMP-dependent protein kinase (PKA; type I and II) that differ in their regulatory subunits, RIα and RIIα. Embryonic lethality of RIα knockout mice limits the current understanding of type I PKA function in the myocardium. The objective of this study was to test the role of RIα in adult heart contractility and pathological remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured PKA subunit expression in human heart and developed a conditional mouse model with cardiomyocyte-specific knockout of RIα (RIα-icKO). Myocardial structure and function were evaluated by echocardiography, histology, and ECG and in Langendorff-perfused hearts. PKA activity and cAMP levels were determined by immunoassay, and phosphorylation of PKA targets was assessed by Western blot. L-type Ca<sup>2+</sup> current (<i>I</i><sub>Ca,L</sub>), sarcomere shortening, Ca<sup>2+</sup> transients, Ca<sup>2+</sup> sparks and waves, and subcellular cAMP were recorded in isolated ventricular myocytes (VMs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RIα protein was decreased by 50% in failing human heart with ischemic cardiomyopathy and by 75% in the ventricles and in VMs from RIα-icKO mice but not in atria or sinoatrial node. Basal PKA activity was increased ≈3-fold in RIα-icKO VMs. In young RIα-icKO mice, left ventricular ejection fraction was increased and the negative inotropic effect of propranolol was prevented, whereas heart rate and the negative chronotropic effect of propranolol were not modified. Phosphorylation of phospholamban, ryanodine receptor, troponin I, and cardiac myosin-binding protein C at PKA sites was increased in propranolol-treated RIα-icKO mice. Hearts from RIα-icKO mice were hypercontractile, associated with increased <i>I</i><sub>Ca,L,</sub> and [Ca<sup>2+</sup>]<sub>i</sub> transients and sarcomere shortening in VMs. These effects were suppressed by the PKA inhibitor, H89. Global cAMP content was decreased in RIα-icKO hearts, whereas local cAMP at the phospholamban/sarcoplasmic reticulum Ca<sup>2+</sup> ATPase complex was unchanged in RIα-icKO VMs. RIα-icKO VMs had an increased frequency of Ca<sup>2+</sup> sparks and proarrhythmic Ca<sup>2+</sup> waves, and RIα-icKO mice had an increased susceptibility to ventricular tachycardia. On aging, RIα-icKO mice showed progressive contractile dysfunction, cardiac hypertrophy, and fibrosis, culminating in congestive heart failure with reduced ejection fraction that caused 50% mortality at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results identify RIα as a key negative regulator of cardiac contractile function, arrhythmia, and pathological remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39355927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39355927</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068858>10.1161/CIRCULATIONAHA.124.068858</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39355927</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ibrahim Bedioune</dc:creator>
<dc:creator>Marine Gandon-Renard</dc:creator>
<dc:creator>Matthieu Dessillons</dc:creator>
<dc:creator>Aurélien Barthou</dc:creator>
<dc:creator>Audrey Varin</dc:creator>
<dc:creator>Delphine Mika</dc:creator>
<dc:creator>Saïd Bichali</dc:creator>
<dc:creator>Joffrey Cellier</dc:creator>
<dc:creator>Patrick Lechène</dc:creator>
<dc:creator>Sarah Karam</dc:creator>
<dc:creator>Maya Dia</dc:creator>
<dc:creator>Susana Gomez</dc:creator>
<dc:creator>Walma Pereira de Vasconcelos</dc:creator>
<dc:creator>Françoise Mercier-Nomé</dc:creator>
<dc:creator>Philippe Mateo</dc:creator>
<dc:creator>Audrey Dubourg</dc:creator>
<dc:creator>Constantine A Stratakis</dc:creator>
<dc:creator>Jean-Jacques Mercadier</dc:creator>
<dc:creator>Jean-Pierre Benitah</dc:creator>
<dc:creator>Vincent Algalarrondo</dc:creator>
<dc:creator>Jérôme Leroy</dc:creator>
<dc:creator>Rodolphe Fischmeister</dc:creator>
<dc:creator>Ana-Maria Gomez</dc:creator>
<dc:creator>Grégoire Vandecasteele</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development</dc:title>
<dc:identifier>pmid:39355927</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068858</dc:identifier>
</item>
<item>
<title>Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39355923/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: RDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medication.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.069709. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Several sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. We aimed to perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We searched MEDLINE and the Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >;70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Ten trials comprising 2478 patients with hypertension while being either off or on treatment were included. Compared with sham, RDN reduced 24-hour and office systolic blood pressure by 4.4 mm Hg (95% CI, 2.7 to 6.1; <i>P</i>&lt;0.00001) and 6.6 mm Hg (95% CI, 3.6 to 9.7; <i>P</i>&lt;0.0001), respectively. The 24-hour and office diastolic blood pressure paralleled these findings (-2.6 mm Hg [95% CI, -3.6 to -1.5]; <i>P</i>&lt;0.00001; -3.5 mm Hg [95% CI, -5.4 to -1.6]; <i>P</i>=0.0003). There was no difference in 24-hour and office systolic blood pressure reduction between trials with and without concomitant antihypertensive medication (<i>P</i> for interaction, 0.62 and 0.73, respectively). There was no relevant difference in vascular complications (odds ratio, 1.69 [95% CI, 0.57 to 5.0]; <i>P</i>=0.34), renal artery stenosis (odds ratio, 1.50 [95% CI, 0.06 to 36.97]; <i>P</i>=0.80), hypertensive crisis (odds ratio, 0.65 [95% CI, 0.30 to 1.38]; <i>P</i>=0.26), and all-cause death (odds ratio, 1.76 [95% CI, 0.34 to 9.20]; <i>P</i>=0.50) between RDN and sham groups. Change of renal function based on estimated glomerular filtration rate was comparable between groups (<i>P</i> for interaction, 0.84). There was significant heterogeneity between trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: RDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medication.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39355923/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39355923</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069709>10.1161/CIRCULATIONAHA.124.069709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39355923</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Davor Vukadinović</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Elazer R Edelman</dc:creator>
<dc:creator>Roland E Schmieder</dc:creator>
<dc:creator>Michel Azizi</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis</dc:title>
<dc:identifier>pmid:39355923</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069709</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39355918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.069378. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction &lt;35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient &lt;50 mm Hg at 1 year. After 6.8 years (range, 3.4-9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1-1.3]; <i>P</i>&lt;0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1-1.2] per 5-year increase; <i>P</i>&lt;0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1-1.8]; <i>P</i>&lt;0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39355918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39355918</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069378>10.1161/CIRCULATIONAHA.124.069378</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39355918</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Niccolò Maurizi</dc:creator>
<dc:creator>Panagiotis Anthiochos</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Neal Lakdwala</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Carlo Fumagalli</dc:creator>
<dc:creator>Ioannis Skalidis</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Ashwin S Nathan</dc:creator>
<dc:creator>Alejandro De Feria Alsina</dc:creator>
<dc:creator>Nosheen Reza</dc:creator>
<dc:creator>John C Stendahl</dc:creator>
<dc:creator>Dominic Abrams</dc:creator>
<dc:creator>Christopher Scemsarian</dc:creator>
<dc:creator>Brian Clagget</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew Wheeler</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan Ashley</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>James Ware</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry</dc:title>
<dc:identifier>pmid:39355918</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069378</dc:identifier>
</item>
<item>
<title>&lt;em>;LRP1&lt;/em>; Repression by SNAIL Results in ECM Remodeling in Genetic Risk for Vascular Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39355906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings support allele-specific LRP1 gene repression by the endothelial-to-mesenchymal transition regulator SNAIL. We propose decreased LRP1 expression in smooth muscle cells to remodel the extracellular matrix enhanced by TGF-β as a potential mechanism of this pleiotropic locus for vascular diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 2. doi: 10.1161/CIRCRESAHA.124.325269. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Genome-wide association studies implicate common genetic variations in the <i>LRP1</i> (low-density lipoprotein receptor-related protein 1) locus at risk for multiple vascular diseases and traits. However, the underlying biological mechanisms are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Fine mapping analyses included Bayesian colocalization to identify the most likely causal variant. Human induced pluripotent stem cells were genome-edited using CRISPR-Cas9 to delete or modify candidate enhancer regions and generate <i>LRP1</i> knockout cell lines. Cells were differentiated into smooth muscle cells through a mesodermal lineage. Transcription regulation was assessed using luciferase reporter assay, transcription factor knockdown, and chromatin immunoprecipitation. Phenotype changes in cells were conducted using cellular assays, bulk RNA sequencing, and mass spectrometry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Multitrait colocalization analyses pointed at rs11172113 as the most likely causal variant in <i>LRP1</i> for fibromuscular dysplasia, migraine, pulse pressure, and pulmonary function trait. We found the rs11172113-T allele to associate with higher <i>LRP1</i> expression. Genomic deletion in induced pluripotent stem cell-derived smooth muscle cells supported rs11172113 to locate in an enhancer region regulating <i>LRP1</i> expression. We found transcription factors MECP2 (methyl CpG binding protein 2) and SNAIL to repress <i>LRP1</i> expression through an allele-specific mechanism, involving SNAIL interaction with disease risk allele. <i>LRP1</i> knockout decreased induced pluripotent stem cell-derived smooth muscle cell proliferation and migration. Differentially expressed genes were enriched for collagen-containing extracellular matrix, connective tissue development, and lung development. <i>LRP1</i> knockout and deletion of rs11172113 enhancer showed potentiated canonical TGF-β (transforming growth factor beta) signaling through enhanced phosphorylation of SMAD2/3. Analyses of the protein content of decellularized extracts indicated partial extracellular matrix remodeling involving enhanced secretion of CYR61, a known LRP1 ligand involved in vascular integrity and TIMP3, implicated in extracellular matrix maintenance and also known to interact with LRP1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings support allele-specific <i>LRP1</i> gene repression by the endothelial-to-mesenchymal transition regulator SNAIL. We propose decreased <i>LRP1</i> expression in smooth muscle cells to remodel the extracellular matrix enhanced by TGF-β as a potential mechanism of this pleiotropic locus for vascular diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39355906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39355906</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325269>10.1161/CIRCRESAHA.124.325269</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39355906</guid>
<pubDate>Wed, 02 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Lu Liu</dc:creator>
<dc:creator>Joséphine Henry</dc:creator>
<dc:creator>Yingwei Liu</dc:creator>
<dc:creator>Charlène Jouve</dc:creator>
<dc:creator>Jean-Sébastien Hulot</dc:creator>
<dc:creator>Adrien Georges</dc:creator>
<dc:creator>Nabila Bouatia-Naji</dc:creator>
<dc:date>2024-10-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>&lt;em>;LRP1&lt;/em>; Repression by SNAIL Results in ECM Remodeling in Genetic Risk for Vascular Diseases</dc:title>
<dc:identifier>pmid:39355906</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325269</dc:identifier>
</item>
<item>
<title>Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352342/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08395-5. doi: 10.1016/j.jacc.2024.08.064. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352342/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39352342</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.064>10.1016/j.jacc.2024.08.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352342</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA</dc:title>
<dc:identifier>pmid:39352342</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.064</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes, or Is it Placebo?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08519-X. doi: 10.1016/j.jacc.2024.09.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39352341</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.021>10.1016/j.jacc.2024.09.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352341</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Torsten B Rasmussen</dc:creator>
<dc:creator>Anne M Dybro</dc:creator>
<dc:creator>Morten Kvistholm Jensen</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes, or Is it Placebo?</dc:title>
<dc:identifier>pmid:39352341</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.021</dc:identifier>
</item>
<item>
<title>Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] &amp; Mortality...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452-3. doi: 10.1016/j.jacc.2024.09.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure (HF) and a recent worsening heart failure (WHF) event are known to be at high risk of recurrent hospitalization and death, regardless of ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study examined the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone in relation to the recency of a WHF event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction ≥40%. In this prespecified analysis, we assessed the risk of cardiovascular (CV) events and response to finerenone vs placebo in relation to the time from WHF to randomization (during or within 7 days, 7 days to 3 months, >;3 months, or no prior WHF). The primary outcome was a composite of total (first and recurrent) WHF events and CV death, analyzed using a proportional rates method.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 6,001 patients validly randomized to finerenone or placebo, 1,219 (20.3%) were enrolled during (749 [12.5%]) or within 7 days (470 [7.8%]), 2,028 (33.8%) between 7 days and 3 months, and 937 (15.6%) >;3 months from a WHF event; 1,817 (30.3%) had no prior history of WHF. Rates of the primary composite outcome varied inversely with time since WHF, with >;2-fold higher risk in those enrolled during or within 7 days of WHF compared with those enrolled >;3 months from WHF or without prior WHF (risk ratio [RR]: 2.13; 95% CI: 1.82-2.55). Compared to placebo, finerenone appeared to lower the risk of the primary composite to a greater extent in those enrolled within 7 days of WHF (RR: 0.74; 95% CI: 0.57-0.95) or between 7 days and 3 months of WHF (RR: 0.79; 95% CI: 0.64-0.97) than in those >;3 months from WHF or without prior WHF (RR: 0.99; 95% CI: 0.81-1.21); however, no definitive treatment-by-time interaction could be confirmed (P = 0.07). Greater absolute risk reductions with finerenone were accordingly seen in those with recent WHF (P<sub>trend</sub> = 0.011). The risk of adverse events including hyperkalemia and worsening renal function among patients assigned to finerenone was not increased in those with recent WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] &amp; Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; A study to gather information on the influence of study drug finerenone on the number of deaths and hospitalizations in participants with heart failure EudraCT 2020-000306-29).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39352340</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.004>10.1016/j.jacc.2024.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352340</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Jonathan Cunningham</dc:creator>
<dc:creator>Maria Borentain</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Katja Rohwedder</dc:creator>
<dc:creator>Flaviana Amarante</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Mikhail Kosiborod</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39352340</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.004</dc:identifier>
</item>
<item>
<title>Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08386-4. doi: 10.1016/j.jacc.2024.09.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient &lt;30 mm Hg and &lt;50 mm Hg, respectively), relief in limiting symptoms (≥1 improvement in NYHA functional class and/or ≥10-point change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score), enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake), and ≥50% reduction in N-terminal pro-B-type natriuretic peptide. Eligibility for septal reduction therapy was also evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 24 weeks, patients treated with aficamten vs placebo showed significant improvement in limiting symptoms (71% vs 42%), were more likely to have complete hemodynamic response (68% vs 7%), demonstrated enhanced exercise capacity (47% vs 24%), and showed a decrease ≥50% in N-terminal pro-B-type natriuretic peptide (84% vs 8%) (P ≤ 0.002 for all). An improvement in ≥1 of these outcome measures was achieved in 97% of patients treated with aficamten (vs 59% placebo), including 23% on aficamten who achieved all 4 outcomes compared with none in placebo. Among 32 patients receiving aficamten and 29 patients receiving placebo who were eligible for septal reduction therapy, 28 (88%) from the aficamten group were no longer eligible at 24 weeks compared with 15 (52%) from the placebo group (P = 0.002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39352339</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.003>10.1016/j.jacc.2024.09.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352339</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Michael Arad</dc:creator>
<dc:creator>Nuno Cardim</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Caroline J Coats</dc:creator>
<dc:creator>Hans-Dirk Düngen</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Albert A Hagège</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Ian Kulac</dc:creator>
<dc:creator>Matthew M Y Lee</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Chang-Sheng Ma</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Artur Oreziak</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:creator>Marion van Sinttruije</dc:creator>
<dc:creator>Josef Veselka</dc:creator>
<dc:creator>Hugh C Watkins</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Amy Wohltman</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>SEQUOIA-HCM Investigators</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM</dc:title>
<dc:identifier>pmid:39352339</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.003</dc:identifier>
</item>
<item>
<title>Time to Significant Benefit of Finerenone in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352338/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 26:S0735-1097(24)08512-7. doi: 10.1016/j.jacc.2024.09.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352338/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39352338</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.018>10.1016/j.jacc.2024.09.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352338</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Time to Significant Benefit of Finerenone in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:39352338</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.018</dc:identifier>
</item>
<item>
<title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 1. doi: 10.1161/CIRCULATIONAHA.124.070039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to studies conducted primarily in middle-aged and elderly populations. This study aimed to assess whether early changes in primary aldosteronism biomarkers during young adulthood are associated with arterial stiffness and left ventricular mass index (LVMI) before the onset of overt disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Raine Study is a longitudinal, population-based cohort study in Western Australia that enrolled women during pregnancy. We analyzed the data from the offspring of these women at 17 (2006-2009) and 27 (2016-2018) years of age. Participants with elevated high-sensitivity C-reactive protein (>;10 mg/L) and female participants who were on oral contraception were excluded. Pulse wave velocity and aortic augmentation index were measured by SphygmoCor Pulse Wave System at both ages, and aortic distensibility and LVMI were measured by cardiac magnetic resonance imaging at 27 years. Multivariable linear regression was used to examine the relationship between plasma renin, aldosterone, or aldosterone-to-renin ratio and arterial stiffness and LVMI. Mediation analysis was used to test the role of systolic blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 859 participants at 17 (38.0% female) and 758 participants at 27 (33.2% female) years of age. Females had lower renin concentration at both 17 (20.7 mU/L versus 25.7 mU/L; <i>P</i>&lt;0.001) and 27 (12.0 mU/L versus 15.4 mU/L; <i>P</i>&lt;0.001) years of age; hence, the aldosterone-to-renin ratio was significantly higher at both 17 (18.2 versus 13.5; <i>P</i>&lt;0.001) and 27 (21.0 versus 15.6; <i>P</i>&lt;0.001) years of age in females compared with males. At 27 years of age, a significant association was detected between aldosterone and LVMI in males (β=0.009 [95% CI, 0.001-0.017]; <i>P</i>=0.027) and between aldosterone-to-renin ratio and LVMI in females (β=0.098 [95% CI, 0.001-0.196]; <i>P</i>=0.050) independently of systolic blood pressure and other confounders. No association was found between primary aldosteronism biomarkers and measures of arterial stiffness (pulse wave velocity, aortic augmentation index, and aortic distensibility) at either age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39351674</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070039>10.1161/CIRCULATIONAHA.124.070039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351674</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roshan A Ananda</dc:creator>
<dc:creator>StellaMay Gwini</dc:creator>
<dc:creator>Lawrence J Beilin</dc:creator>
<dc:creator>Markus P Schlaich</dc:creator>
<dc:creator>Michael Stowasser</dc:creator>
<dc:creator>Morag J Young</dc:creator>
<dc:creator>Brendan Adler</dc:creator>
<dc:creator>Peter J Fuller</dc:creator>
<dc:creator>Trevor A Mori</dc:creator>
<dc:creator>Jun Yang</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</dc:title>
<dc:identifier>pmid:39351674</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070039</dc:identifier>
</item>
<item>
<title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.324938. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39351669</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324938>10.1161/CIRCRESAHA.124.324938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351669</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pegah Ramezani Rad</dc:creator>
<dc:creator>Vanasa Nageswaran</dc:creator>
<dc:creator>Lisa Peters</dc:creator>
<dc:creator>Leander Reinshagen</dc:creator>
<dc:creator>Johann Roessler</dc:creator>
<dc:creator>Szandor Simmons</dc:creator>
<dc:creator>Erik Asmus</dc:creator>
<dc:creator>Corey Wittig</dc:creator>
<dc:creator>Markus C Brack</dc:creator>
<dc:creator>Geraldine Nouailles</dc:creator>
<dc:creator>Emiel P C van der Vorst</dc:creator>
<dc:creator>Sanne L Maas</dc:creator>
<dc:creator>Kristina Sonnenschein</dc:creator>
<dc:creator>Barbara Verhaar</dc:creator>
<dc:creator>Robert Szulcek</dc:creator>
<dc:creator>Martin Witzenrath</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Wolfgang M Kuebler</dc:creator>
<dc:creator>Arash Haghikia</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</dc:title>
<dc:identifier>pmid:39351669</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324938</dc:identifier>
</item>
<item>
<title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.325305. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39351666</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325305>10.1161/CIRCRESAHA.124.325305</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351666</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Manako Yamaguchi</dc:creator>
<dc:creator>Lucas Ferreira de Almeida</dc:creator>
<dc:creator>Hiroki Yamaguchi</dc:creator>
<dc:creator>Xiuyin Liang</dc:creator>
<dc:creator>Jason P Smith</dc:creator>
<dc:creator>Silvia Medrano</dc:creator>
<dc:creator>Maria Luisa S Sequeira Lopez</dc:creator>
<dc:creator>R Ariel Gomez</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</dc:title>
<dc:identifier>pmid:39351666</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325305</dc:identifier>
</item>
<item>
<title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241002224346&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1087-1089. doi: 10.1161/CIRCULATIONAHA.124.071479. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241002224346&v=2.18.0.post9+e462414">39348457</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071479>10.1161/CIRCULATIONAHA.124.071479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348457</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andreas A Giannopoulos</dc:creator>
<dc:creator>Alessia Gimelli</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</dc:title>
<dc:identifier>pmid:39348457</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071479</dc:identifier>
</item>





























</channel>
</rss>